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LETTER TO THE EDITOR
Programmatic implications of the TUMIKIA 
trial on community-wide treatment 
for soil-transmitted helminths: further health 
economic analyses needed before a change 
in policy
Hugo C. Turner1,2*  and Donald A. P. Bundy3
Abstract 
School-based deworming programmes are currently the main approach used to control the soil-transmitted hel-
minths (STHs). A key unanswered policy question is whether mass drug administration (MDA) should be targeted to 
the whole community instead, and several trials in this area have been conducted or are currently on-going. A recent 
well-conducted trial demonstrated that successful community-wide treatment is a feasible strategy for STH control 
and can be more effective than school-based treatment in reducing prevalence and intensity of hookworm infec-
tion. However, we would argue that it is vital that these findings are not taken out of context or over generalised, as 
the additional health benefits gained from switching to community-wide treatment will vary depending on the STH 
species and baseline endemicity. Moreover, community-wide treatment will typically be more expensive than school-
based treatment. The epidemiological evidence for an additional benefit from a switch to community-wide treatment 
has yet to be proven to represent “good value for money” across different settings. Further work is needed before 
changes in policy are made regarding the use of community-wide treatment for STH control, including comprehen-
sive assessments of its additional public health benefits and costs across a range of scenarios, accounting for the 
presence of alternative treatment delivery platforms.
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Letter to the Editor
School-based deworming programmes are currently the 
main approach used to control the soil-transmitted hel-
minths (STHs) [1]. A key unanswered policy question 
is whether mass drug administration (MDA) should be 
targeted to the whole community instead, and several 
trials in this area have been conducted or are currently 
on-going [2–4]. For example, Pullan et  al. [4] recently 
published an impressive and comprehensive trial which 
demonstrated that community-wide treatment of STHs 
in Kenya is possible and can be more effective for reduc-
ing the prevalence and intensity of hookworm (the main 
helminth in the communities studied). Specifically, they 
observed that after 24 months and two rounds of treat-
ment, the overall prevalence of hookworm declined from 
18.6% to 13.8% within the school-based group compared 
to 17.9% to 8.0% within the community-wide treatment 
group. Their findings also highlighted the equity of the 
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community delivery approach and its ability to reach the 
poorest and most marginalised communities.
An important question arises whether these results 
support the policy contention that community-wide 
treatment is cost-effective, and hence should replace 
school-based treatment as the standard method of deliv-
ery for STH control.
In terms of programme effectiveness, there are two 
key outcomes of interest: additional reductions in mor-
bidity and contribution to breaking transmission. Hel-
minth morbidity is typically correlated to the intensity 
of infection, and individuals with moderate to heavy 
intensity infections experience the majority of STH-
related morbidity [5–7]. Due to the non-linear relation-
ship between STH prevalence and intensity [8], when the 
prevalence of infection falls below 20%, the prevalence of 
these moderate to heavy intensity infections is expected 
to be relatively low [9]. Due to this, it is likely that the 
observed additional reductions in prevalence achieved 
by using community-wide treatment would only lead to 
small additional gains in averted morbidity. These find-
ings should not be overgeneralised, and the observed 
benefit may have been partly reduced due to the previ-
ous community-wide treatment for lymphatic filariasis 
that occurred before the study started [4]. In addition, 
mathematical models have also projected larger ben-
efits of community-wide treatment in settings that have 
high baseline prevalence of hookworm [10]. However, 
the additional benefits of community-wide treatment 
would likely be even lower where Ascaris lumbricoides 
and Trichuris trichiura are more prevalent, since unlike 
hookworm, these species typically have much lower lev-
els of infection in adults relative to children [7, 10–12]. 
Consequently, the additional health benefits gained 
from switching to community-wide treatment will vary 
depending on which STH species are endemic, and the 
baseline level of endemicity [10]. It is likely that in at least 
some settings both school-based and community-wide 
approaches can sustain infection below a level likely to be 
associated with significant morbidity.
A potential further benefit of community-wide treat-
ment for STHs is that it may contribute to breaking 
transmission [13, 14]. Typically, treatment is followed 
by re-infection [15], but it is also theorized that suf-
ficient treatment would result in the collapse of trans-
mission (i.e. stochastic extinction), thus removing the 
need for further MDA. Modelling studies have esti-
mated a breakpoint of around 2% prevalence for hook-
worm [16]. However, the reductions in prevalence under 
community-wide treatment in the TUMIKIA study did 
not approach this estimated breakpoint within the trial 
period and the studies available to date in this area have 
not definitively proven breaking transmission is possible 
with either school-based or community-wide treatment. 
The TUMIKIA study also indicates that achieving the 
projected high coverage and compliance levels estimated 
to be required to break transmission in some settings in a 
programmatically realistic time horizon could be difficult 
within many control programmes.
A major consideration regarding the use of com-
munity-wide treatment is its cost [17]. Even when the 
per treatment costs are lower relative to school-based 
strategies, the total cost will typically be higher because 
more individuals are treated. This is illustrated with an 
example in Table  1. Although this is a crude calcula-
tion, it indicates that even with conservative, at-scale 
estimates, the total cost of community-wide treat-
ment is likely to be more expensive than the total cost 
of school-based treatment. Does the additional benefit 
outweigh this larger investment and greater complex-
ity of implementation: is community-based treatment 
good value for money or cost-effective? Further stud-
ies are needed to obtain more accurate estimates of 
the difference in these costs [17]. There is potential for 
Table 1 Hypothetical case study of the estimated financial costs of using different treatment strategies within the Kenyan national 
STH control programme
a Approximated based on demographic data from the World Bank [24]
b Based on the WHO MDA cost benchmark model [25]
c Estimate from Evidence Action (a programmatic estimate for 2015) [23]
d Based on the estimate from the TUMIKIA trial [4]: routine scenario (excluding the research costs) relating to whole county (i.e. estimate at scale). US$0.025 per 
treatment was added for the cost of albendazole [4]
e Based on the estimate from the TUMIKIA trial [4]—routine scenario (excluding the research costs) relating to trial areas only. US$0.025 per treatment was added for 
the cost of albendazole [4]
Strategy Number treated Assumed cost per treatment (US$) Estimated total 
financial cost per year 
(US$)
School-based treatment 6 million children [23] 0.30b–0.56c 1.8–3.4 million
Community-wide treatment 14 million  individualsa 0.32d–0.46e 4.4–6.4 million
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community-wide treatment to be cost-saving in the 
long term if it can stop the need for further treatment 
[10], but this is contingent on the interruption of trans-
mission in an appropriate timescale, which has yet to 
be demonstrated.
To conclude, the TUMIKIA study is an important 
and well-conducted trial which demonstrates that suc-
cessful community-wide treatment is a feasible strategy 
for STH control and can be more effective than school-
based treatment in reducing prevalence and intensity of 
hookworm infection. However, these results should not 
be taken out of context, and achieving marginally greater 
reductions in already low prevalence settings did not 
necessarily lead to significant public health benefits or 
break transmission. Yet, community-wide treatment will 
typically be more expensive than school-based treatment. 
This does not mean that a community-wide treatment 
is never cost-effective [18, 19], but it does indicate that 
there are many contexts where switching to community-
wide treatment would not yield notable public health 
benefits compared to remaining with school-based treat-
ment. The policy implications of these results should not 
be over-interpreted or be extrapolated to all contexts. 
Ongoing studies (such as DeWorm3) are assessing the 
capacity of community-wide treatment for breaking STH 
transmission [3], which could importantly change the 
policy implications, but this approach currently remains 
unproven. Importantly, community-wide mass treatment 
is not the only strategy to provide treatment to adults 
and it is probable that building on established health 
system approaches (such as using child health days and 
antenatal clinics) to deliver treatment could offer a way 
of treating adults at a lower cost [20, 21]. Further work 
is needed before changes in policy are made regarding 
the use of community-wide treatment for STH control, 
including comprehensive assessments of its additional 
public health benefits and costs across a range of scenar-
ios, accounting for the presence of alternative treatment 
delivery platforms for reaching at-risk groups other than 
school-aged children [21, 22].
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